The chess game among Gilead, AbbVie, pharmaceutical benefit managers and health plans on expensive but effective Hepatitis C treatments is well underway. I’ve been following the story for quite a while –and asked all of the candidates for Massachusetts Governor about it a year ago.
Now I’m being interviewed about it, most recently for AIS’s Health Plan Week (Health Plans Join in Action as PBMs Make Exclusive Deals for Competing Hep C drugs). The publication is behind a firewall but includes my skepticism that Express Scripts will accomplish very much with its tough stance.
I’m expecting to be quoted in other articles soon, and may write about the topic later this week.